Tracking at lower end of range on forecast ebit margin. So, still undervalued but may see a few cheapies come out from those who were expecting more. Or maybe not. Seems to be tightly held.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025
ASX Market Open: Futures say drop after Bullock's hawkish speech removes slow cut doubts | Nov 29, 2024